Ruijiao J. Zhao
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Folate Receptor Alpha Expression Across the Spectrum of Serous Tubal Lesions: An Adjunct Biomarker for Distinguishing Serous Tubal Intraepithelial Carcinoma From Serous Tubal Intraepithelial Lesions.
Journal: The American journal of surgical pathology
Published: June 25, 2026
Thermal ablation for visible cervical HSIL or suspected HSIL: a tissue-conserving alternative to excision in selected patients.
Journal: Frontiers in oncology
Published: March 18, 2026
Comparative Evaluation of E6/E7 mRNA Expression and Viral DNA Load in Cervical Lesions with Multiple High-Risk HPV Infection.
Journal: The Journal of infectious diseases
Published: February 20, 2026
Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial.
Journal: Cancer
Published: September 05, 2025
Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis.
Journal: Neuro-oncology advances
Published: September 04, 2025
A study of HPV self-sampling by female residents in communities of Zhengzhou, Henan Province, China: a cross-sectional observational study.
Journal: Frontiers in public health
Published: January 09, 2025
Residual disease volume and prognosis in endometrioid precancer after progestin therapy.
Journal: Virchows Archiv : an international journal of pathology
Published: December 10, 2024
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.
Journal: Journal of cancer research and clinical oncology
Published: June 18, 2024
Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas.
Journal: Neurosurgery
Published: June 09, 2024
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.
Journal: Cancer immunology, immunotherapy : CII
Published: May 08, 2024
Last Updated: 09/26/2026